GTLB:NASDAQGitLab Inc. Analysis
Data as of 2026-04-07 - not real-time
$22.76
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
GitLab (GTLB) is trading at $22.76, just above its 20‑day SMA ($22.23) but well below the 50‑day ($27.01) and 200‑day ($39.45) averages, indicating short‑term momentum but a longer‑term bearish backdrop. The stock sits near its technical support at $20.20 with resistance around $24.83, while the RSI of 44.7 suggests neutral pricing and a bullish MACD histogram (+0.44) hints at a possible near‑term upside. Volatility remains high at nearly 60% over the past 30 days and a beta of ~1.42 points to heightened market sensitivity, yet the company boasts strong fundamentals: 23% YoY revenue growth, an 87% gross margin, positive free cash flow of $283 M, and a cash pile exceeding $1.2 B with zero debt. A DCF‑derived fair value of $64.67 implies roughly 50% upside, far outpacing the industry’s average forward P/E of 32.5, and analysts collectively rate the stock as a “Buy” with a mean target of $34.2.
The recent earnings release highlighted robust ARR expansion and the launch of a share‑repurchase program, reinforcing confidence in cash generation and shareholder returns. Despite current operating losses, the forward EPS projection of $1.02 and a solid cash runway position GitLab for a turnaround, especially as it expands its AI‑driven DevSecOps platform. Given the valuation gap, cash strength, and strategic growth initiatives, the stock presents a compelling case for investors with a higher risk tolerance seeking long‑term upside.
The recent earnings release highlighted robust ARR expansion and the launch of a share‑repurchase program, reinforcing confidence in cash generation and shareholder returns. Despite current operating losses, the forward EPS projection of $1.02 and a solid cash runway position GitLab for a turnaround, especially as it expands its AI‑driven DevSecOps platform. Given the valuation gap, cash strength, and strategic growth initiatives, the stock presents a compelling case for investors with a higher risk tolerance seeking long‑term upside.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price marginally above 20‑day SMA and near support level
- Bullish MACD histogram despite broader bearish trend
- High short‑term volatility and decreasing volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF upside of ~50% and forward P/E below industry average
- Strong revenue growth (23%) and robust free cash flow
- Share‑repurchase program signaling confidence in balance sheet
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strategic expansion of AI‑enabled DevSecOps platform
- Large cash cushion with zero debt supporting future investment
- Significant valuation gap to fair value providing long‑term upside
Key Metrics & Analysis
Financial Health
Revenue Growth23.20%
Profit Margin-5.86%
P/E Ratio22.3
ROE-6.30%
ROA-2.72%
P/B Ratio3.9
Op. Cash Flow$232.9M
Free Cash Flow$283.1M
Industry P/E32.5
Technical Analysis
TrendBearish
RSI44.7
Support$20.20
Resistance$24.83
MA 20$22.23
MA 50$27.01
MA 200$39.45
MACDBullish
VolumeDecreasing
Fear & Greed Index76.52
Valuation
Fair Value$64.67
Target Price$34.20
Upside/Downside50.26%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.42
Volatility59.67%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.